ORS 646A.697 Study of market for generic drugs; effect of pricing on insurance premiums; report to Legislative Assembly

As used in this section, “generic drug” means:

A retail drug that is marketed or distributed in accordance with an abbreviated new drug application approved under 21 U.S.C. 355(j);

An authorized generic as defined by 42 C.F.R. 447.502; or

A drug that entered the market before 1962 that was not originally marketed under a new drug application.

The Prescription Drug Affordability Board shall annually conduct a study of the operation of the United States market for generic drugs, both drugs dispensed by pharmacists and drugs administered by physicians, including:

The prices of generic drugs on a year-to-year basis;

The degree to which generic drug prices affect insurance premiums;

Annual changes in health insurance cost-sharing for generic drugs;

The potential for and history of generic drug shortages;

The degree to which generic drug prices affect annual spending in the state medical assistance program; and

Any other topic the board considers relevant to the cost of generic drugs.

No later than June 1 of each calendar year, the board shall report to the Legislative Assembly the findings of the board’s study in the manner provided in ORS 192.245.